No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials

References

• Garbe E, Andersohn F, Bronder E, et al. Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study. Br J Haematol. 2011;154(5):644–653. doi:10.1111/j.1365-2141.2011.08784.x21749359
   PubMed Web of Science ®Google Scholar
• Pierce A, Nester T. Pathology consultation on drug-induced hemolytic anemia. Am J Clin Pathol. 2011;136(1):7–12. doi:10.1309/AJCPBVLJZH6W6RQM21685026
   PubMed Web of Science ®Google Scholar
• Habibi B. Drug induced red blood cell autoantibodies co-developed with drug specific antibodies causing haemolytic anaemias. Br J Haematol. 1985;61(1):139–143. doi:10.1111/j.1365-2141.1985.tb04069.x2864949
   PubMed Web of Science ®Google Scholar
• Mueller-Eckhardt C, Salama A. Drug-induced immune cytopenias: a unifying pathogenetic concept with special emphasis on the role of drug metabolites. Transfus Med Rev. 1990;4(1):69–77. doi:10.1016/S0887-7963(90)70249-02151995
   PubMedGoogle Scholar
• Salama A. Drug-induced immune hemolytic anemia. Expert Opin Drug Saf. 2009;8(1):73–79. doi:10.1517/1474033080257735119236219
   PubMed Web of Science ®Google Scholar
• Branch DR. Drug-induced immune haemolytic anaemias. ISBT Sci Ser. 2019;14(1):49–52. doi:10.1111/voxs.12469
   Google Scholar
• Parker V, Tormey CA. The direct antiglobulin test: indications, interpretation, and pitfalls. Arch Pathol Lab Med. 2017;141(2):305–310. doi:10.5858/arpa.2015-0444-RS28134589
   PubMed Web of Science ®Google Scholar
• Zantek ND, Koepsell SA, Tharp DR Jr, Cohn CS. The direct antiglobulin test: a critical step in the evaluation of hemolysis. Am J Hematol. 2012;87(7):707–709. doi:10.1002/ajh.2321822566278
   PubMed Web of Science ®Google Scholar
• Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. Immunohematology. 2014;30(2):66–79.25247621
   PubMedGoogle Scholar
• Arndt PA, Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol. 2005;42(3):137–144. doi:10.1053/j.seminhematol.2005.04.00416041663
   PubMed Web of Science ®Google Scholar
• Mayer B, Bartolmäs T, Yürek S, Salama A. Variability of findings in drug-induced immune haemolytic anaemia: experience over 20 years in a single centre. Transfus Med Hemother. 2015;42(5):333–339. doi:10.1159/00044067326696803
   PubMed Web of Science ®Google Scholar
• Arndt PA, Leger RM, Garratty G. Serology of antibodies to second- and third-generation cephalosporins associated with immune hemolytic anemia and/or positive direct antiglobulin tests. Transfusion. 1999;39(11–12):1239–1246. doi:10.1046/j.1537-2995.1999.39111239.x10604252
   PubMed Web of Science ®Google Scholar
• Arndt PA, Leger RM, Garratty G. Serologic characteristics of ceftriaxone antibodies in 25 patients with drug-induced immune hemolytic anemia. Transfusion. 2012;52(3):602–612. doi:10.1111/j.1537-2995.2011.03321.x21880048
   PubMed Web of Science ®Google Scholar
• Northrop MS, Agarwal HS. Ceftriaxone-induced hemolytic anemia: case report and review of literature. J Pediatr Hematol Oncol. 2015;37(1):e63–66. doi:10.1097/MPH.000000000000018124878619
   PubMed Web of Science ®Google Scholar
• Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):iv67–iv71. doi:10.1093/jac/dkq25621115456
   PubMed Web of Science ®Google Scholar
• Goodman JJ, Martin SI. Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections. Ther Clin Risk Manag. 2012;8:149–156.22547933
   PubMed Web of Science ®Google Scholar
• Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl 3):iii53–iii59. doi:10.1093/jac/dkr09921482570
   PubMed Web of Science ®Google Scholar
• Allergan. TEFLARO® (ceftaroline fosamil) prescribing information. 2019 Available from: https://media.allergan.com/actavis/actavis/media/allergan-pdf-documents/product-prescribing/Teflaro-USPI-09_2019-2.pdf. Accessed August, 2020.
   Google Scholar
• Liapikou A, Cilloniz C, Torres A. Ceftobiprole for the treatment of pneumonia: a European perspective. Drug Des Devel Ther. 2015;9:4565–4572.
   PubMedGoogle Scholar
• Electronic Medicines Compendium. Zevtera 500 mg powder for concentrate for solution for infusion. 2018 Available from: https://www.medicines.org.uk/emc/product/9164. Accessed August, 2020.
   Google Scholar
• Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 2008;52(1):37–44. doi:10.1128/AAC.00551-0717954698
   PubMed Web of Science ®Google Scholar
• Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008;46(5):647–655. doi:10.1086/52652718225981
   PubMed Web of Science ®Google Scholar
• Nicholson SC, Welte T, File TM Jr, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012;39(3):240–246. doi:10.1016/j.ijantimicag.2011.11.00522230331
   PubMed Web of Science ®Google Scholar
• Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014;59(1):51–61. doi:10.1093/cid/ciu21924723282
   PubMed Web of Science ®Google Scholar
• NCT3439124. Ceftobiprole in the treatment of pediatric patients with pneumonia. 2020 Available from: https://clinicaltrials.gov/ct2/show/NCT3439124. Accessed August, 2020.
   Google Scholar
• Overcash J, Kim C, Keech R, et al. Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: results of a Phase 3, randomized, double-blind trial (TARGET). Clin Infect Dis. In press 2020. doi:10.1093/cid/ciaa974
   Web of Science ®Google Scholar
• Hamed K, Engelhardt M, Jones ME, et al. Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, phase III trial. Future Microbiol. 2020;15:35–48. doi:10.2217/fmb-2019-033231918579
   PubMed Web of Science ®Google Scholar
• Kim TO, Grimes AB, Kirk S, et al. Association of a positive direct antiglobulin test with chronic immune thrombocytopenia and use of second line therapies in children: a multi-institutional review. Am J Hematol. 2019;94(4):461–466. doi:10.1002/ajh.2540930663792
   PubMed Web of Science ®Google Scholar
• Roehmel J, Specht P, Staab D, Schwarz C, Salama A, Mayer B. Risk of piperacillin-induced hemolytic anemia in patients with cystic fibrosis and antipseudomonal treatment: a prospective observational study. Transfusion. 2019;59(12):3746–3754. doi:10.1111/trf.1559131724753
   PubMed Web of Science ®Google Scholar